Highlights
- Third quarter net loss was USD 50,369 thousand, or USD 0.15 per share.
- Cash, cash equivalents and investments were USD 388.9 million at September 30, 2026.
- Nine-month net loss narrowed to USD 135,653 thousand from USD 152,076 thousand.
- Total stockholders' Equity rose to USD 392,552 thousand from USD 292,542 thousand.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) shares were trading near their 52-week low at USD 1.03 on November 6, 2026, down 5.50% on the day. The clinical stage company reported a third quarter net loss of USD 50,369 thousand, or USD 0.15 per share, and USD 388.9 million in cash, cash equivalents and investments.
Allogene has a market Capitalization of about USD 355.86 million at the current price. It is a clinical stage immuno-oncology company developing genetically engineered allogeneic T cell product candidates for cancer and autoimmune diseases.
Third Quarter Results
Total operating expenses were USD 54,793 thousand against USD 44,901 thousand, and the loss from operations was USD 54,793 thousand against USD 44,901 thousand. General and administrative expenses were USD 12.9 million against USD 13.7 million, and interest and other income, net was USD 4.9 million against USD 3.9 million. The net loss was USD 50,369 thousand against USD 41,400 thousand, or USD 0.15 per share against USD 0.19.
Nine-Month Results
Total operating expenses were USD 152,445 thousand against USD 166,911 thousand, and the loss from operations was USD 147,805 thousand against USD 166,911 thousand. The net loss was USD 135,653 thousand against USD 152,076 thousand, or USD 0.44 per share against USD 0.70.
Pipeline
The company is developing cema-cel, which is in the ALPHA3 trial, and ALLO-329, a next generation allogeneic CAR T product candidate targeting both CD19 and CD70 for certain autoimmune diseases. ALLO-329 uses the Dagger technology, which is designed to reduce or eliminate the need for standard chemotherapy. Analyst questions on the quarter centered on ALPHA3 enrollment pace ahead of an interim event free survival look in mid-2027.
Cash Flow and Balance Sheet
Cash and cash equivalents were USD 29,270 thousand against USD 51,688 thousand at December 31, 2025, and the company held USD 388.9 million in cash, cash equivalents and investments. For the nine months, net cash used in Operating Activities was USD 81,027 thousand against USD 121,647 thousand, net cash used in investing activities was USD 151,031 thousand against cash provided of USD 61,946 thousand, and net cash provided by financing activities was USD 209,640 thousand against USD 22,298 thousand.
Total Assets were USD 511,320 thousand against USD 415,905 thousand. Total liabilities were USD 118,768 thousand against USD 123,363 thousand, and total stockholders' equity was USD 392,552 thousand against USD 292,542 thousand. The accumulated Deficit was USD 2,146,362 thousand.






Please wait processing your request...